Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686805 | 0.98 | NOS2 (0.44) | L3MBTL1NOS2MAPTSMN1; SMN2CES2 | |
| SCHEMBL817467 | 0.96 | NOS2 (0.42) | L3MBTL1NOS2MAPTSMN1; SMN2CES2 | |
| SCHEMBL816881 | 0.96 | NOS2 (0.42) | L3MBTL1NOS2MAPTSMN1; SMN2CES2 | |
| SCHEMBL817534 | 0.96 | NOS2 (0.42) | L3MBTL1NOS2MAPTSMN1; SMN2CES2 | |
| SCHEMBL817527 | 0.86 | L3MBTL1 (0.44) | L3MBTL1NOS2SMN1; SMN2CES2CES1 | |
| SCHEMBL3682396 | 0.84 | CES2 (0.44) | L3MBTL1NOS2SMN1; SMN2CES2CES1 | |
| SCHEMBL817375 | 0.82 | CES2 (0.43) | L3MBTL1NOS2SMN1; SMN2CES2CES1 | |
| SCHEMBL816329 | 0.82 | CES2 (0.43) | L3MBTL1NOS2SMN1; SMN2CES2CES1 | |
| SCHEMBL817754 | 0.82 | CES2 (0.43) | L3MBTL1NOS2SMN1; SMN2CES2CES1 | |
| SCHEMBL8016277 | 0.81 | CES2 (0.47) | CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153545-B2 | Process for homo—or copolymerization of conjugated olefins | STYRON EUROPE GMBH (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20110160041-A1 | PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS | STYRON EUROPE GMBH | 2011-06-30 | — | — | US | disclosed |
| US-7915194-B2 | Process for homo- or copolymerization of conjugated olefins | STYRON EUROPE GMBH (CH) | 2011-03-29 | — | — | US | disclosed |
| US-20100248947-A1 | PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7612009-B2 | Process for homo-or copolymerization of conjugated olefines | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060142145-A1 | Process for homo-or copolymerization of conjugated olefines | TRINSEO EUROPE GMBH (CH) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160041-A1 | PROCESS FOR HOMO - OR COPOLYMERIZATION OF CONJUGATED OLEFINS | F12, ETFB, F2 | L3MBTL1 1885/4885NOS2 2904/4885MAPT 4598/4885 |
| US-20060142145-A1 | Process for homo-or copolymerization of conjugated olefines | ETFB, F12, F2 | L3MBTL1 2053/4885NOS2 2830/4885MAPT 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.